Irene Stefanaki

Athens, ESYE31, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

A high-penetrance intergenic variant at 9p21 confers melanoma susceptibility.

A high-penetrance intergenic variant at 9p21 confers melanoma susceptibility.

Journal: Research square

Published: May 25, 2026

A high-penetrance intergenic variant at 9p21 confers melanoma susceptibility.

A high-penetrance intergenic variant at 9p21 confers melanoma susceptibility.

Journal: Research square

Published: May 25, 2026

Drug survival of bimekizumab, guselkumab, and risankizumab after secondary IL-17 inhibitor failure.

Drug survival of bimekizumab, guselkumab, and risankizumab after secondary IL-17 inhibitor failure.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: May 05, 2026

Impact of vitamin D receptor gene variants on psoriasis vulgaris susceptibility and clinical phenotype in a Greek population.

Impact of vitamin D receptor gene variants on psoriasis vulgaris susceptibility and clinical phenotype in a Greek population.

Journal: Experimental and therapeutic medicine

Published: December 14, 2025

Diagnostic insights into a case of pigmented extramammary Paget's disease mimicking melanoma.

Diagnostic insights into a case of pigmented extramammary Paget's disease mimicking melanoma.

Journal: Anais brasileiros de dermatologia

Published: November 07, 2025

Divergent pathways of melanoma development: evidence from a Southern European cohort.

Divergent pathways of melanoma development: evidence from a Southern European cohort.

Journal: Melanoma research

Published: September 08, 2025

Genetic susceptibility in early-onset melanoma: An observational Greek cohort study.

Genetic susceptibility in early-onset melanoma: An observational Greek cohort study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: July 29, 2025

Long-Term Outcomes of Guselkumab and Risankizumab for the Management of Moderate-to-Severe Psoriasis in the Elderly: Results from a Real-World Retrospective Study.

Long-Term Outcomes of Guselkumab and Risankizumab for the Management of Moderate-to-Severe Psoriasis in the Elderly: Results from a Real-World Retrospective Study.

Journal: Journal of clinical medicine

Published: July 25, 2025

Switching within the class of IL-23 inhibitors for the treatment of psoriasis: A systematic review.

Switching within the class of IL-23 inhibitors for the treatment of psoriasis: A systematic review.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: May 23, 2025

Long-term effectiveness, safety and prognostic factors of response to treatment with bimekizumab in patients with plaque psoriasis: results from a real-world multicentre study.

Long-term effectiveness, safety and prognostic factors of response to treatment with bimekizumab in patients with plaque psoriasis: results from a real-world multicentre study.

Journal: Clinical and experimental dermatology

Published: May 12, 2025

Guselkumab Is Effective for the Management of Scalp Psoriasis in Both Biologic-Naïve and Biologic-Experienced Patients: Results From a Real-World, Retrospective Study.

Guselkumab Is Effective for the Management of Scalp Psoriasis in Both Biologic-Naïve and Biologic-Experienced Patients: Results From a Real-World, Retrospective Study.

Journal: International journal of dermatology

Published: March 28, 2025

Targeting IL-23 in Generalized Pustular Psoriasis: Clinical Success With Guselkumab in an Elderly Patient With Comorbidities.

Targeting IL-23 in Generalized Pustular Psoriasis: Clinical Success With Guselkumab in an Elderly Patient With Comorbidities.

Journal: International journal of dermatology

Published: March 10, 2025

Showing 1-12 of 46

Last Updated: 09/26/2026